Stifel
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
338% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 21
151% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $10.5M
15% more funds holding
Funds holding: 438 [Q3] → 502 (+64) [Q4]
14% more capital invested
Capital invested by funds: $8.17B [Q3] → $9.28B (+$1.11B) [Q4]
0.62% more ownership
Funds ownership: 84.85% [Q3] → 85.46% (+0.62%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q3] → 8 (+0) [Q4]
7% less repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 171
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
21%
upside
Avg. target
$126
33%
upside
High target
$135
42%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
UBS Brennan Hawken 52% 1-year accuracy 17 / 33 met price target | 27%upside $120 | Neutral Maintained | 3 Feb 2025 |
JMP Securities Devin Ryan 64% 1-year accuracy 41 / 64 met price target | 42%upside $135 | Market Outperform Maintained | 30 Jan 2025 |
Wells Fargo Michael Brown 46% 1-year accuracy 30 / 65 met price target | 42%upside $135 | Overweight Maintained | 30 Jan 2025 |
Citigroup Christopher Allen 74% 1-year accuracy 14 / 19 met price target | 21%upside $115 | Neutral Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 9 articles about SF published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 1:00 p.m. ET.
Neutral
Business Wire
4 days ago
ATTENTION STIFEL BROKERAGE CUSTOMERS: Kaskela Law LLC Announces Class Action Lawsuit Filed Against Stifel Nicolaus & Co. Inc. and Encourages Brokerage Customers to Contact the Firm to Discuss Their Legal Rights and Options
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that a class action lawsuit has been filed against Stifel Nicolaus & Co., Inc. (“Stifel”) on behalf of certain Stifel customers who maintained brokerage accounts with automatic cash sweep programs. According to the complaint, “Stifel violated its fiduciary, contractual, and implied duties by underpaying its clients to enrich itself and its affiliates at its clients' expense. Rather than pay clients a fair and reasonable rate of intere.
Neutral
GlobeNewsWire
5 days ago
Stifel Reports February 2025 Operating Data
ST. LOUIS, March 27, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for February 28, 2025 in an effort to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed.
Positive
Proactive Investors
5 days ago
Pantheon International offers value, says Stifel
Pantheon International PLC (LSE:PIN) has been reiterated at 'buy' by analysts at Stifel, who see value in the shares following a recent de-rating. With the shares trading at around 302p, this represents a discount of approximately 40% to the latest reported NAV of 509p at 31 January 2025.
Neutral
CNBC Television
1 week ago
Stifel's Barry Bannister: A relief rally has been underway but there could be a dip later this year
Barry Bannister, Stifel chief equity strategist, joins CNBC's 'Squawk on the Street' to discuss market outlooks, how to position, and more.
Negative
Market Watch
2 weeks ago
Stifel ordered to pay $132 million for allegedly misleading investor on risky structured notes
A Finra panel said Stifel was “required to have heightened supervision” of a broker.
Positive
Zacks Investment Research
2 weeks ago
5 Stocks With Attractive Price-to-Sales Ratios for Smart Investing
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SANM, PAGS, ROCK, PRAA and SF hold promise.
Neutral
CNBC Television
3 weeks ago
Stifel Financial CEO Ron Kruszewski: This is a normal correction considering the new administration
Ron Kruszewski, Stifel Financial chairman and CEO, joins 'Squawk Box' to discuss the latest market trends, what to make of the recent market volatility, state of the financials sector, and more.
Neutral
GlobeNewsWire
3 weeks ago
Stifel Appoints Jonathan Siegmann as Managing Director Covering Aerospace and Defense Sector
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today appointed Jonathan Siegmann as Managing Director of Equity Research, covering the aerospace and defense industry. He will be based in the firm's Boston office.
Neutral
GlobeNewsWire
1 month ago
Stifel Celebrates Mikaela Shiffrin's Historic 100th Win With Donation to Her “MIK100” Initiative
ST. LOUIS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Stifel (NYSE: SF), the official team naming partner of the Stifel U.S. Alpine Ski Team, is proud to celebrate the 100th career World Cup victory for Mikaela Shiffrin this past weekend as she captured first place in slalom in Sestriere, Italy, by supporting her efforts to raise $100,000 for the Share Winter Foundation.
Charts implemented using Lightweight Charts™